Novel potent inhibitors of Plasmodium vivax dihydrofolate reductase: An in silico antimalarial drug discovery

dc.contributor.authorPushpendra, Singh
dc.contributor.authorKushwaha, Prem Prakash
dc.contributor.authorShashank, Kumar
dc.date.accessioned2018-02-20T05:52:23Z
dc.date.accessioned2024-08-13T10:34:54Z
dc.date.available2018-02-20T05:52:23Z
dc.date.available2024-08-13T10:34:54Z
dc.date.issued2018
dc.description.abstractObjectives: In the present study, we targeted the dihydrofolate reductase enzyme that catalyzes the reduction of dihydrofolate to tetrahydrofolate which is required for the purines and pyrimidine synthesis. Malaria is one of the severe diseases throughout the world caused by blood-borne parasite Plasmodium vivax. Materials and Methods: Eighty-five parthenin analogs were docked against P. vivax and Homo sapiens dihydrofolate reductase proteins (PDB 2BL9 and 1KMS respectively) by using Maestro 9.6 program to evaluate the binding affinities of ligands with the protein. Results and Discussion: Docking analysis revealed some best hit ligands against P. vivax such as CID3467446 and CID56671343 but not inhibited the mammalian dihydrofolate reductase. The Dock score of parthenin analogs ranged from -7.31 to -9.3 while for standard dihydrofolate reductase inhibitors it was -4.78 to -8.04. Structural analysis of docked complexes of selected parthenin like compounds with P. vivax and mammalian dihydrofolate reductase revealed the involvement of Arg 115, Leu 136, Lys 138, Gly 175, Ser 117, Gln 177 and Ile 7, Ala 9, Thr 56, Ile 60, Pro 61 amino acid residues respectively in strong interactions. Absorption, distribution, metabolism, and excretion properties of best-docked compounds were predicted using QikProp application of Maestro 9.6. The results indicated that all the best-docked lead compounds followed Lipinski?s rule of five. Conclusion: Based on the results of the present study it has been concluded that parthenin like compounds may serve as potent dihydrofolate reductase inhibition based anti-malarial drug lead. ? 2018, Association of Pharmaceutical Teachers of India. All rights reserved.en_US
dc.identifier.citationPushpendra, S., Prem, K. P., & Kumar, S. (2018). Novel potent inhibitors of Plasmodium vivax dihydrofolate reductase: An in silico antimalarial drug discovery. Indian Journal of Pharmaceutical Education and Research, 52(1), 122-134. doi: 10.5530/ijper.52.1.14en_US
dc.identifier.doi10.5530/ijper.52.1.14
dc.identifier.issn195464
dc.identifier.urihttps://kr.cup.edu.in/handle/32116/599
dc.identifier.urlhttp://www.ijper.org/article/789
dc.language.isoenen_US
dc.publisherAssociation of Pharmaceutical Teachers of Indiaen_US
dc.subjectAmino aciden_US
dc.subjectAntimalarial agenten_US
dc.subjectDihydrofolate reductaseen_US
dc.subjectDihydrofolate reductase inhibitoren_US
dc.subjectParthenin binding affinityen_US
dc.subjectCatalysisen_US
dc.subjectControlled studyen_US
dc.subjectDrug absorptionen_US
dc.subjectDrug distributionen_US
dc.subjectDrug excretionen_US
dc.subjectDrug metabolismen_US
dc.subjectDrug structureen_US
dc.subjectHumanen_US
dc.subjectMolecular dockingen_US
dc.subjectNon humanen_US
dc.subjectPhysical chemistryen_US
dc.subjectPlasmodium vivaxen_US
dc.subjectSoftwareen_US
dc.titleNovel potent inhibitors of Plasmodium vivax dihydrofolate reductase: An in silico antimalarial drug discoveryen_US
dc.title.journalIndian Journal of Pharmaceutical Education and Research
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Shashank k 3.pdf
Size:
1.03 MB
Format:
Adobe Portable Document Format

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Plain Text
Description: